Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2025-01-31 Declaration of Voting R…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Antalet aktier och röster i Xbrane har förändrats till följd av att 2 706 898 aktier har emitterats under januari månad genom utnyttjande av teckningsoptioner i december 2025.
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states that the total number of shares and votes has changed due to the issuance of 2,706,898 new shares through the exercise of warrants. This directly relates to a change in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the core content is the capital change itself, not just the announcement of a report, making SHA more specific than RPA or RNS. The text mentions the information is being made public under financial instrument trading laws, confirming its regulatory nature.
2025-01-31 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” eller “bolaget) utser Jane Benyamin till tillförordnad Chief Financial Officer.
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new interim Chief Financial Officer (CFO) at Xbrane Biopharma AB. It details the departure of the previous CFO and the background of the incoming appointee. This falls directly under the category of management changes.
2025-01-09 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new acting Chief Financial Officer (CFO) at Xbrane Biopharma AB. This falls directly under the category of management changes, which is defined as 'Announcement of changes in the company's board of directors or senior management'.
2025-01-09 English
Xbrane Biopharma AB (publ) (“Xbrane” eller “bolaget) utser Jane Benyamin till tillförordnad Chief Financial Officer.
Board/Management Information Classification · 100% confidence The document announces the appointment of a new interim Chief Financial Officer (CFO), Jane Benyamin, and the departure of the current CFO, Anette Lindqvist. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and appears to be a press release announcing this personnel change, fitting the MANG category perfectly.
2025-01-09 Swedish
Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.
Board/Management Information Classification · 100% confidence The document explicitly announces a change in senior management: the appointment of Jane Benyamin as acting Chief Financial Officer (CFO) and the stepping down of the current CFO, Anette Lindqvist. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2025-01-09 English
XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that Xbrane Biopharma AB has resubmitted a Biologics License Application (BLA) to the FDA for a biosimilar candidate. It details the previous rejection (CRL) and the steps taken to address FDA feedback. The document is very short (2684 characters) and concludes with an attachment link and a statement about information being made public under EU Market Abuse Regulation. This structure—a brief announcement about a regulatory/corporate event with an attached document—strongly suggests it is a general regulatory announcement rather than a comprehensive report (like 10-K or IR). Since it doesn't fit specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate fallback category for a general, time-sensitive regulatory disclosure is Regulatory Filings (RNS).
2024-12-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.